These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 9603404

  • 1. Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation.
    Gowing H, Braakman E, Hagenbeek A, Lawler M, McCann SR, Pamphilon DH, Martens AC.
    Bone Marrow Transplant; 1998 Apr; 21(8):801-7. PubMed ID: 9603404
    [Abstract] [Full Text] [Related]

  • 2. Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia.
    Kloosterman TC, Tielemans MJ, Martens AC, van Bekkum DW, Hagenbeek A.
    Bone Marrow Transplant; 1994 Jul; 14(1):15-22. PubMed ID: 7951103
    [Abstract] [Full Text] [Related]

  • 3. Graft-versus-leukemia in rat MHC-mismatched bone marrow transplantation is merely an allogeneic effect.
    Kloosterman TC, Martens AC, van Bekkum DW, Hagenbeek A.
    Bone Marrow Transplant; 1995 Apr; 15(4):583-90. PubMed ID: 7655385
    [Abstract] [Full Text] [Related]

  • 4. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM, Omdal BK, Dai KZ, Martens A, Benestad HB, Vaage JT, Rolstad B.
    Transplantation; 2008 Jan 15; 85(1):102-11. PubMed ID: 18192919
    [Abstract] [Full Text] [Related]

  • 5. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 6. The mechanism of UVB prevention of graft versus host disease.
    Greenfeld JI, Chabot JA, Oluwole SF, Hardy MA.
    J Surg Res; 1996 Jan 15; 60(1):137-41. PubMed ID: 8592404
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-2 therapy after allogeneic bone marrow transplantation for acute myelocytic leukemia: studies in a relevant rat model for AML.
    Kloosterman TC, Martens AC, Osterwalder B, Hagenbeek A.
    Bone Marrow Transplant; 1994 Dec 15; 14(6):965-73. PubMed ID: 7711675
    [Abstract] [Full Text] [Related]

  • 8. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH, Li DP, Zhang YJ, Zhang P, Zeng LY, Pan XY, Xu KL, Huang YH.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb 15; 33(2):88-93. PubMed ID: 22730654
    [Abstract] [Full Text] [Related]

  • 9. Prevention of cyclosporine-induced syngeneic graft-versus-host disease in bone marrow transplantation by UV-B irradiated bone marrow cells.
    Ohajekwe OA, James T, Hardy MA, Oluwole SF.
    Bone Marrow Transplant; 1995 Apr 15; 15(4):627-32. PubMed ID: 7655391
    [Abstract] [Full Text] [Related]

  • 10. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L.
    Bone Marrow Transplant; 1990 Sep 15; 6(3):155-61. PubMed ID: 2252954
    [Abstract] [Full Text] [Related]

  • 11. Graft-versus-leukemia effect in allogeneic bone marrow transplantation in mice against several radiation-induced leukemias.
    Aizawa S, Sado T, Kamisaku H, Nemoto K, Yoshida K.
    Bone Marrow Transplant; 1994 Feb 15; 13(2):109-14. PubMed ID: 8205078
    [Abstract] [Full Text] [Related]

  • 12. Ganciclovir-mediated elimination of HSV-Tk+ T cells and cure of graft-vs-host disease in an allogeneic bone marrow transplantation model in the rat.
    Weijtens M, van Spronsen A, Hagenbeek A, de Weger R, Martens A.
    Exp Hematol; 2004 Oct 15; 32(10):962-9. PubMed ID: 15504552
    [Abstract] [Full Text] [Related]

  • 13. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
    Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA.
    J Immunol; 1997 Oct 01; 159(7):3460-73. PubMed ID: 9317145
    [Abstract] [Full Text] [Related]

  • 14. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y, Guo K, Chen Y, Song Z, Li J, Deng L.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug 01; 23(8):411-4. PubMed ID: 12411044
    [Abstract] [Full Text] [Related]

  • 15. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
    Aizawa S, Kamisaku H, Sado T.
    Bone Marrow Transplant; 1995 Oct 01; 16(4):603-9. PubMed ID: 8528179
    [Abstract] [Full Text] [Related]

  • 16. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA.
    Dan Med Bull; 2002 May 01; 49(2):89-108. PubMed ID: 12064093
    [Abstract] [Full Text] [Related]

  • 17. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
    Sykes M, Bukhari Z, Sachs DH.
    Bone Marrow Transplant; 1989 Sep 01; 4(5):465-74. PubMed ID: 2790325
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L, Reich S, Slavin S.
    Cytokines Cell Mol Ther; 1999 Sep 01; 5(3):145-52. PubMed ID: 10641572
    [Abstract] [Full Text] [Related]

  • 19. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
    Sykes M, Sharabi Y, Sachs DH.
    Bone Marrow Transplant; 1988 Sep 01; 3(5):379-86. PubMed ID: 3056545
    [Abstract] [Full Text] [Related]

  • 20. Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
    Li JM, Giver CR, Waller EK.
    Exp Hematol; 2006 Jul 01; 34(7):895-904. PubMed ID: 16797417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.